Analysis of MRD values obtained from clinical samples (n = 36) of six ALL patients revealed a significant correlation (R2 = 0.9121, P < 0.0001) between the Ig/TCR and patient-specific CDKN2A/B assays designed in our study. Here, CDKN2A is linked to acute lymphoblastic leukemia.